Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 4/20 | 0.33 |
| ▸ | RAB9A | P51151 | 4/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3040220 | 0.89 | KMT2A (0.36) | MAPTGAAKDM4ETHRBALDH1A1 | |
| SCHEMBL13971212 | 0.73 | — | — | |
| SCHEMBL3040193 | 0.73 | KMT2A (0.38) | MAPTGAAALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL11738618 | 0.69 | GAA (0.52) | MAPTGAAKDM4ETHRBALDH1A1 | |
| SCHEMBL21875055 | 0.68 | KMT2A (0.45) | MAPTLMNAALDH1A1RAB9AKMT2A | |
| SCHEMBL27633763 | 0.67 | MAPT (0.73) | MAPTGAAKDM4ETHRBALDH1A1 | |
| SCHEMBL3043609 | 0.66 | ATR (0.44) | KMT2A | |
| SCHEMBL17637643 | 0.64 | MAPT (0.73) | MAPTGAAKDM4ETHRBLMNA | |
| SCHEMBL17637668 | 0.63 | MAPT (0.69) | MAPTGAAKDM4ETHRBLMNA | |
| SCHEMBL2000856 | 0.63 | LMNA (0.52) | MAPTGAAKDM4ETHRBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2170872-A2 | PROCESS FOR THE PREPARATION OF BENZIMIDAZOL THIENYLAMINE COMPOUNDS AND INTERMEDIATES THEREOF | Sanofi-Aventis U.S. LLC (US) | 2010-04-07 | — | — | EP | claimed |
| WO-2009006066-A2 | PROCESS FOR THE PREPARATION OF BENZIMIDAZOL THIENYLAMINE COMPOUNDS AND INTERMEDIATES THEREOF | SANOFI-AVENTIS U.S. LLC (US) | 2009-01-08 | — | — | WO | claimed |
| EP-2170872-B1 | PROCESS FOR THE PREPARATION OF THE N-(2-CHLORO-4-METHYL-3-THIENYL)-1H- BENZIMIDAZOL-2-AMINE HYDROCHLORIDE AND INTERMEDIATES THEREOF | SANOFI AVENTIS US LLC (US) | 2010-09-01 | — | — | EP | disclosed |
| EP-2170872-B1 | PROCESS FOR THE PREPARATION OF THE N-(2-CHLORO-4-METHYL-3-THIENYL)-1H- BENZIMIDAZOL-2-AMINE HYDROCHLORIDE AND INTERMEDIATES THEREOF | SANOFI AVENTIS US LLC (US) | 2010-09-01 | — | — | EP | disclosed |
| US-20100174088-A1 | PROCESS FOR THE PREPARATION OF BENZIMIDAZOL THIENYLAMINE COMPOUNDS AND DERIVATIVES THEREOF USEFUL AS SODIUM/PROTON EXCHANGER TYPE 3 INHIBITORS | SANOFI-AVENTIS U.S. LLC (US) | 2010-07-08 | — | — | US | disclosed |
| US-20100174088-A1 | PROCESS FOR THE PREPARATION OF BENZIMIDAZOL THIENYLAMINE COMPOUNDS AND DERIVATIVES THEREOF USEFUL AS SODIUM/PROTON EXCHANGER TYPE 3 INHIBITORS | SANOFI-AVENTIS U.S. LLC (US) | 2010-07-08 | — | — | US | disclosed |
| US-20100174088-A1 | PROCESS FOR THE PREPARATION OF BENZIMIDAZOL THIENYLAMINE COMPOUNDS AND DERIVATIVES THEREOF USEFUL AS SODIUM/PROTON EXCHANGER TYPE 3 INHIBITORS | SANOFI-AVENTIS U.S. LLC (US) | 2010-07-08 | — | — | US | disclosed |
| EP-2170872-A2 | PROCESS FOR THE PREPARATION OF BENZIMIDAZOL THIENYLAMINE COMPOUNDS AND INTERMEDIATES THEREOF | Sanofi-Aventis U.S. LLC (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009006066-A2 | PROCESS FOR THE PREPARATION OF BENZIMIDAZOL THIENYLAMINE COMPOUNDS AND INTERMEDIATES THEREOF | SANOFI-AVENTIS U.S. LLC (US) | 2009-01-08 | — | — | WO | disclosed |
| WO-2009006066-A2 | PROCESS FOR THE PREPARATION OF BENZIMIDAZOL THIENYLAMINE COMPOUNDS AND INTERMEDIATES THEREOF | SANOFI-AVENTIS U.S. LLC (US) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100174088-A1 | PROCESS FOR THE PREPARATION OF BENZIMIDAZOL THIENYLAMINE COMPOUNDS AND DERIVATIVES THEREOF USEFUL AS SODIUM/PROTON EXCHANGER TYPE 3 INHIBITORS | SLC9A3, NHERF1, SLC9A5 | MAPT 4075/4885GAA 1214/4885KDM4E 1734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.